SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
https://www.zacks.com/stock/news/2261546/syk-vs-zbh-which-stock-looks-more-promising-ahead-of-q1-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-2261546
Apr 24, 2024 - SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.
0
Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay
https://www.zacks.com/stock/news/2257016/henry-schein-hsic-global-presence-aids-macroeconomic-woes-stay?cid=CS-ZC-FT-analyst_blog|zer_report_update-2257016
Apr 17, 2024 - Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
0
Here's Why You Should Retain Chemed (CHE) Stock for Now
https://www.zacks.com/stock/news/2257026/here-s-why-you-should-retain-chemed-che-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2257026
Apr 17, 2024 - Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2256314/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2256314
Apr 16, 2024 - Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
0
Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
https://www.zacks.com/stock/news/2254645/hologic-s-holx-new-launches-aid-macroeconomic-issues-ail?cid=CS-ZC-FT-analyst_blog|zer_report_update-2254645
Apr 12, 2024 - Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
0
Smith+Nephew (SNN) Expands in Australia With New Alliance
https://www.zacks.com/stock/news/2253858/smith-nephew-snn-expands-in-australia-with-new-alliance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253858
Apr 11, 2024 - The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
0
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
https://www.zacks.com/stock/news/2252692/here-s-why-you-should-retain-myriad-genetics-mygn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252692
Apr 09, 2024 - Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
0
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
https://www.zacks.com/stock/news/2251992/abbott-abt-faces-low-testing-demand-currency-headwinds?cid=CS-ZC-FT-analyst_blog|zer_report_update-2251992
Apr 08, 2024 - Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
0
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
https://www.zacks.com/stock/news/2251935/im-cannabis-imcc-expands-business-in-germany-with-new-alliance?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2251935
Apr 08, 2024 - The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
0
Here's Why You Should Retain Penumbra (PEN) Stock for Now
https://www.zacks.com/stock/news/2252020/here-s-why-you-should-retain-penumbra-pen-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2252020
Apr 08, 2024 - Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
0
Page 1>